The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation (LACE)

Ligand Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Bone Loss

Treatments: Drug: Lasofoxifene; Other: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00674453

A2181042

Details and patient eligibility

About

The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.

Enrollment: 51 patients

Sex: Female

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Postmenopausal women over 50 years who have low bone mineral density.

Exclusion criteria

• Women who are under 50 years of age, are premenopausal, or who currently have osteoporosis are excluded.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

51 participants in 2 patient groups, including a placebo group

Lasofoxifene 0.25 mg/d

Experimental group

Treatment:

Drug: Lasofoxifene

Placebo

Placebo Comparator group

Treatment:

Other: Placebo